Doxofylline: Advancing and Empowering Equitable Asthma and COPD Management Beyond Tradition

Abstract Doxofylline, a newer methylxanthine derivative, has garnered increasing attention for its distinct pharmacological properties and therapeutic advantages over traditional agents such as theophylline. This paper provides a comprehensive review of the pharmacological characteristics and clinical efficacy of doxofylline, elucidating why it represents a significant advancement in methylxanthine therapy. Moreover, attention is given to the economic considerations surrounding its utilization, particularly in low‐ and medium‐income countries where access to healthcare resources is limited. The affordability, improved tolerability, and dosing convenience of doxofylline make it a promising candidate for addressing the substantial burden of asthma and COPD in resource‐constrained settings.